Neuron23 sat down with movement disorders specialist Danielle Larson, MD, to break down exactly what LRRK2 is.
Published
Signal category
Research & Knowledge
Quote
“We sat down with Danielle Larson, MD, a movement disorders specialist, to break down exactly what #LRRK2 is.”
— Neuron23 team
Company
Neuron23
Combining cutting-edge science, human genetics, and a patient-centered approach to transform how we treat Parkinson’s.
- Industry
- Biotechnology Research
- Location
- South San Francisco, US
- Company size
- 29 employees
Neuron23 Inc. is a clinical-stage biotechnology company focused on developing precision medicines for Parkinson’s disease driven by hyperactive LRRK2. Neuron23 combines advances in human genetics with a state-of-the-art drug discovery and biomarker platform, leveraging advanced techniques in machine learning and artificial intelligence to advance therapeutics aimed at impacting disease progression. The company’s focus is on transforming the future of treatment for PD through innovation, collaboration, and dedication to enhancing patient outcomes. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.
Founded 2018